Longeveron Inc. Class A Common Stock (LGVN)
Stock · NASDAQ · Health Care
$1.38as of 10/16/2026
Price chart
Active signals
LGVN Signal Track Record
How signals performed across all stocks →What LGVN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | -13.9% | 22% | September 16, 2026 |
| Bollinger Band Breakdown | 27 | +0.4% | 52% | July 6, 2026 |
| Bollinger Band Breakout | 16 | -16.0% | 19% | August 27, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -17.5% | 0% | August 3, 2026 |
| Any 20-session window (baseline) | -8.4% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clini…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 38
- Website
- www.longeveron.com/
Fundamentals
- 1-day range
- $1.36$1.49
- Market cap
- $24.44M
- P/E (trailing)
- —
- P/E (forward)
- -0.93
- EPS (trailing)
- $-6.72
- Dividend yield
- —
- Beta
- 0.86
- Avg. volume
- 98.1K
How Longeveron Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 14, 2023 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Longeveron Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- ATNMActinium Pharmaceuticals Inc. (Delaware) Common Stock$1.13▲ 6.60%Market cap $24.69MP/E 2.95$0.7351$1.74
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- AYTUAytu BioPharma Inc. Common Stock$2.04▲ 1.49%Market cap $25.01MP/E —$1.8$3.07
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) Common Stock | $24.69M | 2.95 | $1.13 | ▲ 6.60% | $0.7351$1.74 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| AYTU Aytu BioPharma Inc. Common Stock | $25.01M | — | $2.04 | ▲ 1.49% | $1.8$3.07 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Longeveron to Participate in Three Longevity/Aging Investment ConferencesYahoo · 9/30/2026
- Longeveron ELPIS II Trial Did Not Meet Primary Efficacy EndpointBenzinga · 9/23/2026
- Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?Yahoo · 9/22/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 9/18/2026
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drugYahoo · 9/18/2026
- Top movers in Thursday's sessionChartMill · 9/17/2026
- Here are the top movers in Thursday's session.ChartMill · 9/17/2026
- Let's uncover which stocks are experiencing notable gaps during today's session.ChartMill · 9/17/2026
Insider Activity
Insider Actions →- Jhaveri Nirav S. · October 1, 2026 · Tax Withholding742 @ $2.59
- Nataliya Agafonova · October 1, 2026 · Tax Withholding2.9K @ $2.59
- Paul T. Lehr · October 1, 2026 · Tax Withholding2.3K @ $2.59
- Devin Blass · October 1, 2026 · Tax Withholding2.5K @ $2.59
- Stephen H. Willard · October 1, 2026 · Tax Withholding2.0K @ $2.59
- Paul T. Lehr · August 19, 2026 · Grant286.0K
- Roger Joseph Hajjar · August 19, 2026 · Grant36.0K
- Rock Soffer · August 19, 2026 · Grant36.0K
- George A. Paletta Jr. · August 19, 2026 · Grant36.0K
- Ungaro Ursula · August 19, 2026 · Grant36.0K
- Desai Arjun JJ · August 19, 2026 · Grant36.0K
- Devin Blass · August 19, 2026 · Grant286.0K
- Nataliya Agafonova · August 19, 2026 · Grant286.0K
- Ascheim Deborah · August 19, 2026 · Grant36.0K
- Cann Leah Rush · August 19, 2026 · Grant36.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.24M
- Total value held
- $2.21M
- Institutional holders
- 30
- Unknown542.0K
- Unknown446.7K
- Unknown224.2K
- Unknown203.6K
- Unknown200.0K
- Unknown185.7K
- Unknown118.9K
- Unknown100.0K
- Unknown45.4K
- Unknown26.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences
Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.